Vancouver, Canada – January 27, 2025 – Delays in diagnosing axial spondyloarthritis (axSpA) have been a persistent challenge, with many patients waiting 7 to 10 years for an accurate diagnosis. These delays can lead to missed opportunities for early treatment and a higher risk of long-term complications.
We’re proud to share that the Spondylitis Association of America (SAA) has recognized the impact of the Anti-14-3-3eta Multiplex Biomarker in addressing these challenges. In their latest issue of the eSUN newsletter, the biomarker is featured as a significant innovation in axSpA diagnosis and care.
The article highlights how this innovative biomarker aims to addresses long-standing challenges in diagnosing axSpA, enabling:
- Faster and more accurate diagnoses
- Earlier treatment and better symptom management
- Improved patient outcomes
By analyzing autoantibodies associated with the 14-3-3eta protein, Anti-14-3-3eta Multiplex offers real-time insights into the disease and provides clinicians with an important tool to help confidently diagnose axSpA early. Research shows Anti-14-3-3eta Multiplex can identify up to 90% of axSpA cases when combined with CRP.
To learn more about Anti-14-3-3eta Multiplex and its potential to transform axSpA patient outcomes, read the full article in the SAA’s eSUN newsletter:
About Augurex
Augurex is a commercial stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test which detects the 14-3-3eta protein, available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs expand Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which if untreated can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.
Media Contact
Nima Mazinani
604-674-8231